+

WO2002038163A1 - Mastic osseux et son procede - Google Patents

Mastic osseux et son procede Download PDF

Info

Publication number
WO2002038163A1
WO2002038163A1 PCT/US2001/044848 US0144848W WO0238163A1 WO 2002038163 A1 WO2002038163 A1 WO 2002038163A1 US 0144848 W US0144848 W US 0144848W WO 0238163 A1 WO0238163 A1 WO 0238163A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone
water
demineralized
supernatant
gel
Prior art date
Application number
PCT/US2001/044848
Other languages
English (en)
Inventor
El Gendler
Eli Gendler
Simon Gendler
Original Assignee
El Gendler
Eli Gendler
Simon Gendler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by El Gendler, Eli Gendler, Simon Gendler filed Critical El Gendler
Priority to EP01993469A priority Critical patent/EP1341545B1/fr
Priority to DE60140142T priority patent/DE60140142D1/de
Priority to AT01993469T priority patent/ATE444759T1/de
Publication of WO2002038163A1 publication Critical patent/WO2002038163A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/46—Special tools for implanting artificial joints
    • A61F2/4644—Preparation of bone graft, bone plugs or bone dowels, e.g. grinding or milling bone material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30059—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in bone mineralization, e.g. made from both mineralized and demineralized adjacent parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • This invention pertains to a bone matrix suspension in forms suitable for surgical grafting or other medical uses and a method for making same.
  • Malleable bone putty or bone gel is used to correct surgical defects that may be caused by trauma, pathological disease, surgical intervention or other situations where defects need to be managed in osseous surgery. It is important to have the defect filler in the form of a stable, viscous gel or putty to facilitate the placement of the bone growth medium into the surgical site which is usually uneven in shape and depth. The surgeon will take the gel or putty on a spatula or other instrument and trowel it into the site or take it in his/her fingers to shape the bone inducing material into the proper configuration to fit the site being corrected.
  • Specific monosaccharides in blood are glucose at a concentration of 60- 100 mg/ 100 ml (0.1 %) and polysaccharides such as hexose and glucosamine at approximately 0.1%.
  • Glucuronic acid is also present at approximately 0.4-1.4 mg/100 ml (average 0.01%).
  • the problems inherent with using the patient's blood as a carrier for demineralized bone powder are the difficulties of mixing the same at the operating site, the difficulty in obtaining a bone paste consistency which can be easily applied to the surgical area, the guesswork in mixing a usable composition at the site and the problem of having a bone paste or gel which will promote optimum bone replacement growth and not be carried away by the body fluids at the operation site or simply fall out of the bone defect site.
  • Demineralized allograft bone matrix (DBM) is produced from banked human bone taken from cadavers.
  • Demineralized allograft bone is usually available in a lyophilized or freeze dried and sterile form - such as cubes, shavings, or powder - to provide for extended shelf life.
  • the bone in this form is usually very coarse and dry and is difficult to manipulate by the surgeon.
  • GRAFTON® a registered trademark of Osteotech Inc.
  • GRAFTON® a registered trademark of Osteotech Inc.
  • GRAFTON® works well to allow the surgeon to place the allograft bone material at the site.
  • the carrier, glycerol has a very low molecular weight (92 Daltons) and is very soluble in water - the primary component of the blood which flows at the surgical site.
  • Glycerol also experiences a marked reduction in viscosity when its temperature rises from room temperature (typically 22° C in an operating room) to the temperature of the patient's tissue, typically 37° C. This combination of high water solubility and reduced viscosity causes the allograft bone material to be "runny" and to flow away from the site almost immediately after placement; this prevents the proper retention of the bone within the site as carefully placed by the surgeon.
  • GRAFTON® gel have been attempted to be resolved by using a much larger particle size of allograft bone, specifically lamellae or slivers of bone created by milling or slicing the bone before mixing it with the glycerol carrier.
  • the larger particles of demineralized bone may also retard the development of new bone by the patient because the large bony lamellae do not pack as well as the smaller grainy particles of bone. This will leave more open space and could lengthen the tine required to grow new bone and properly fill the defect.
  • Another deficiency of using the bony lamellae is that the ends of the bony fragments are uneven and when packed into the surgical defect, leave uneven filaments of bone protruding out from the defect which can compromise the healing rate.
  • U.S. Patent No. 5,290,558 discloses a flowable demineralized bone powder composition using a osteogenic bone powder with a large particle size ranging from about 0.1 to about 1.2 cm, mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.
  • No. 4,172,1208 which discloses demineralized bone material mixed with a carrier used to reconstruct tooth or bone material, and made by adding a mucopolysaccharide to a mineralized bone colloidal material.
  • the composition is formed from a demineralized coarsely ground bone material, which may be derived from human bones and teeth, dissolved in a solvent forming a colloidal solution to which is added a physiologically inert polyhydroxy compound such as mucopolysaccharide or polyuronic acid in an amount which causes orientation when hydrogen ions or polyvalent metal ions are added to form a gel.
  • the gel will be flowable at elevated temperatures above 35°C and will solidify when brought down to body temperature.
  • Example 25 of the patent notes that mucopolysaccharides produce pronounced ionotropic effects and that hyaluronic acid is particularly responsible for spatial cross-linking. Unfortunately this bone gel is difficult to manufacture and requires a pre-molded gel form.
  • U.S. Patent No. 4,191,747 teaches a bone defect treatment with coarsely ground, denatured bone meal freed from fat and ground into powder.
  • the bone meal is mixed with a polysaccharide in a solution of saline and applied to the bone defect site.
  • Another prior art product is the formulation of demineralized allograft bone particles in collagen.
  • Bovine collagen carries the risk of an immunogenic reaction by the recipient patient.
  • BSE bovine spongioform encephalopathy
  • bovine tissue carries a risk of disease transmission and is not a desirable carrier for allograft tissue.
  • Human collagen is free of these animal based diseases. However, collagen absorbs slowly in the human body, particularly in a bony site with usually a low degree of vascularity. The slow absorption of collagen can delay the growth of new bone and result in the formation of scar tissue at the site. This could result in a non-bony healing and a result with much less tensile strength.
  • U.S. Patent No. 6,030,635 describes a method for making a bone putty or gel in which bone powder is suspended in a carrier that is selected from the group consisting of sodium hyaluronate, chitosan and N,O-carboxymethylchitosan, in water solution.
  • a carrier selected from the group consisting of sodium hyaluronate, chitosan and N,O-carboxymethylchitosan, in water solution.
  • the use of other hydrogels is also disclosed.
  • a disadvantage of such a composition is that it employs as a carrier synthetic components that may not be well tolerated in vivo. Accordingly, the prior art as embodied in the glycerol and other carrier based technology to deliver demineralized allograft bone to a surgical osseous site is replete with problems and only partially addresses the problems inherent in the correcting surgical defects. A need exists for a bone gel or putty free from the disadvantages of the prior art.
  • a bone gel or putty has been discovered that uses aqueous dissolved demineralized bone as the carrier in which bone particles are suspended.
  • the carrier may also comprise additional components such as those normally found in blood serum.
  • the carrier is non-toxic and does not adversely impact the patient.
  • the present invention also provides an easy method for the production of bone gel or bone putty that is biocompatible, non-inflammatory, capable of inducing
  • the aforementioned gel or putty can be made extremely malleable while retaining its structural and dimensional integrity both prior to and after hydration and additionally possessing significant tensile strength.
  • the aqueous dissolved demineralized bone used as the carrier may be formed in any advantageous manner.
  • a supernatant may be formed by dissolving demineralized allograft bone matrix, in the form of cubes, shavings, or powders, in either water or a solution comprising water and at least one component normally found in animal blood serum (e.g., sodium chloride, potassium phosphate, sodium bicarbonate, or the like) at a temperature of above about 25° C.
  • animal blood serum e.g., sodium chloride, potassium phosphate, sodium bicarbonate, or the like
  • dissolution is enhanced by the use of agitation and/or ultrasound.
  • the dissolution may also be enhanced by use of pressure.
  • the pressure will be at least about 15 psi, for a period of time.
  • the resulting viscous supernatant is then cooled and mixed with demineralized or non-demineralized bone powder or shavings to form a gel-like or putty-like suspension.
  • the supernatant is obtained by heating to a temperature between about 85° C and about 100° C.
  • a viscous supernatant is formed from the demineralized bone.
  • the bone dissolution is continued under the elevated temperature for a period of time sufficient to generate a supernatant having a viscosity above about 1 centipoise; more particularly, the heating is continued to the point where a thick, viscous liquid has been formed, which usually takes place between about 24 and about 120 hours.
  • the supernatant is then allowed to cool.
  • the heated solution is subjected to an elevated pressure of at least about 15 psi, more preferably between about 15 psi and about 90 psi, the bone is dissolved more readily.
  • the use of pressure to dissolve the demineralized bone matrix is faster, in that the process, depending on the amount of pressure used, usually only needs to be carried out from between about 1 hour to about 8 hours.
  • the further advantage lies in that there may not need to be any mechanical agitation, as the elevated pressure compensates for this.
  • the supernatant is then cooled. Once cooled, the viscous supernatant is mixed with either demineralized or non-demineralized bone powder or shavings. As this is done, the mixture will achieve, at first, a gel-like texture. At this point, a bone gel has been formed from the mixture of a supernatant with suspended demineralized bone particles and demineralized or non-demineralized bone powder or shavings. However, more demineralized or non-demineralized bone powder or shavings may be added in order to achieve a putty-like texture. Usually the amount of dissolved demineralized bone will be from about 0.5 to about 25 percent, by weight, based on the total weight of water and bone, preferably from about 5 to about 10 percent.
  • the demineralized bone used to make the carrier may be in any physical form, such as chips, shavings or particles.
  • the form of the demineralized bone used to make the carrier is not critical, as it ultimately will be dissolved. The use of smaller particles will aid in the dissolution process.
  • Sufficient demineralized bone is dissolved to increase the viscosity of the water. Preferably the viscosity is increased to from about 2 to about 100 centipoises, preferably from about 40 to about 200 centipoises. Alternatively sufficient demineralized bone is dissolved to convert the carrier into a gel or gel-like structure.
  • the water may be sterile water for injection or sterile saline solution or may comprise other components, such as those normally found in blood, such as BSS balanced salt solution, containing 140 mM NaCl, 5.4 mM KC1, at a pH of 7.6.
  • Soluble calcium can be attracted to the surgical site by using a sodium phosphate buffer of pH 7.2 in lieu of the isotonic saline.
  • the phosphate buffer will attract calcium cations to the site from the surrounding healthy bone and create an equilibrium concentration of the calcium precisely at the site of healing where it is most desirable to grow new bone.
  • bone powder or shavings are added to form a gel-like or putty-like suspension.
  • the bone that is added may be demineralized or non- demineralized bone , or a mixture thereof, and may be in the physical form of chips, shavings or powder.
  • the bone has an average particle size of from about 10 to about 850 microns, more preferably from about 250-500 microns.
  • the amount of suspended bone that is present in the final product usually will be from about 5 to about 50 percent by weight, based on the total weight of the suspension, preferably from about 7 to about 30 percent, and most preferably from about 10 to about 20 percent.
  • EXAMPLE 1 This example demonstrates a novel method of making a bone gel with a useful bulk viscosity and optimum bioabsorbability.
  • Demineralized bone powder with particle size of 45-125 ⁇ m is placed in distilled water boiling at 100° C.
  • the solution is constantly agitated by magnetic stirring and/or ultrasound for 72 hours, at which point a viscous supernatant has been produced.
  • the supernatant is then set out for several hours to cool, and then mixed with demineralized bone powder to form a gel-like suspension.
  • EXAMPLE 2 This example demonstrates a novel method of making a bone putty with a useful bulk viscosity and optimum bioabsorbability.
  • Demineralized bone powder with particle size of 45-125 ⁇ m is placed in distilled water boiling at 100° C.
  • the solution is constantly agitated by magnetic stirring and/or ultrasound for 72 hours, at which point a viscous supernatant has been produced.
  • the supernatant is then set out for several hours to cool, and then mixed with demineralized bone shavings to form a putty-like material.
  • This example demonstrates a novel method of making a bone gel with a useful bulk viscosity and optimum bioabsorbability.
  • Demineralized bone powder with a particle size of 45-125 ⁇ m is placed in distilled boiling water and autoclaved at a temperature of 110-115° C and at a pressure of 20-22 psi for about 3 hours, at which point a viscous supernatant is produced. The supernatant is then set out for several hours to cool, and then mixed with demineralized bone powder to form a gel-like suspension.
  • This example demonstrates a novel method of making a bone putty with a useful bulk viscosity and optimum bioabsorbability.
  • Demineralized bone powder with a particle size of 45- 125 ⁇ m is placed in distilled boiling water and autoclaved at a temperature of 110-115° C and at a pressure of 20-22 psi for about 3 hours, at which point a viscous supernatant is produced. The supernatant is then set out for several hours to cool, and then mixed with demineralized bone shavings to form a putty-like material.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un procédé de préparation de gel et de mastic osseux consistant à produire un surnageant visqueux par dissolution dans l'eau d'une matrice osseuse déminéralisée, ou une solution comprenant de l'eau et au moins un composant trouvé normalement dans un sérum sanguin humain, à une température supérieure à environ 25 °C. L'agitation, et/ou les ultrasons, ou la pression accélèrent la dissolution de l'os déminéralisé. Le supernageant visqueux résultant est refroidi, puis mélangé avec des particules de matrice déminéralisée ou non afin de former une suspension de type gel ou un matériau de type mastic.
PCT/US2001/044848 2000-11-13 2001-11-01 Mastic osseux et son procede WO2002038163A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01993469A EP1341545B1 (fr) 2000-11-13 2001-11-01 Procédé de préparation d'un mastic osseux
DE60140142T DE60140142D1 (de) 2000-11-13 2001-11-01 Verfahren zur herstellung eines knochenzements
AT01993469T ATE444759T1 (de) 2000-11-13 2001-11-01 Verfahren zur herstellung eines knochenzements

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/711,716 2000-11-13
US09/711,716 US6576249B1 (en) 2000-11-13 2000-11-13 Bone putty and method

Publications (1)

Publication Number Publication Date
WO2002038163A1 true WO2002038163A1 (fr) 2002-05-16

Family

ID=24859218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044848 WO2002038163A1 (fr) 2000-11-13 2001-11-01 Mastic osseux et son procede

Country Status (6)

Country Link
US (1) US6576249B1 (fr)
EP (1) EP1341545B1 (fr)
AT (1) ATE444759T1 (fr)
DE (1) DE60140142D1 (fr)
RU (1) RU2003117454A (fr)
WO (1) WO2002038163A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003324A3 (fr) * 2005-06-30 2007-08-16 Transtissue Technologies Gmbh Greffon acellulaire
EP1891990A3 (fr) * 2006-04-19 2008-04-23 Biomet Manufacturing Corp. Composition et appareil pour la réparation osseuse
EP2144672A1 (fr) * 2007-05-04 2010-01-20 Perth Bone & Tissue Bank Procédé et matériau à libération contrôlée pour traiter l'inflammation
EP2349365A1 (fr) * 2008-11-04 2011-08-03 Perth Bone & Tissue Bank Matériau de support pour des cellules ostéogéniques
CN102232073A (zh) * 2008-09-16 2011-11-02 普罗克西梅根有限公司 新化合物i
US8734828B2 (en) 2006-10-06 2014-05-27 Biotissue Ag Matrix-gel graft without cells

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US20130101675A1 (en) * 2001-09-06 2013-04-25 Nicolaas Duneas Cross-Linked Non-Demineralized Collagenous Biomaterial
US20050152986A1 (en) * 2001-09-06 2005-07-14 Nicolaas Duneas Cross-linked collagenous biomaterial
US7744597B2 (en) 2002-06-26 2010-06-29 Lifenet Health Device and process for producing fiber products and fiber products produced thereby
US7498040B2 (en) 2005-10-12 2009-03-03 Lifenet Health Compositions for repair of defects in osseous tissues, and methods of making the same
US7494811B2 (en) 2003-05-01 2009-02-24 Lifenet Health In vitro growth of tissues suitable to the formation of bone and bone forming tissue formed thereby
CA2539568C (fr) 2003-09-23 2013-09-10 Orthotherapeutics, Llc Implants absorbables et leurs procedes d'utilisation pour une hemostase et pour traiter des defauts osseux
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US7989000B2 (en) 2003-09-23 2011-08-02 Orthocon, Inc. Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects
US20050074476A1 (en) * 2003-10-03 2005-04-07 El Gendler Cartilidge and bone induction by artificially perforated organic bone matrix augmented by undifferentiated cells suspended in bone gel
US7534264B2 (en) * 2004-01-28 2009-05-19 Ultradent Products, Inc. Delivery system for bone growth promoting material
US7678385B2 (en) * 2004-04-28 2010-03-16 Biomet Manufacturing Corp. Irradiated implantable bone material
US20050244450A1 (en) * 2004-04-28 2005-11-03 Reddi A H Heat-treated implantable bone material
US8603528B2 (en) * 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
US20060083769A1 (en) 2004-10-14 2006-04-20 Mukesh Kumar Method and apparatus for preparing bone
US20070083270A1 (en) * 2005-10-12 2007-04-12 Leila Masinaei Orthopedic prosthetic devices containing compositions for repair of defects in osseous tissues
US7498041B2 (en) * 2005-10-12 2009-03-03 Lifenet Health Composition for repair of defects in osseous tissues
US9005646B2 (en) 2005-10-12 2015-04-14 Lifenet Health Compositions for repair of defects in tissues, and methods of making the same
US20070092494A1 (en) * 2005-10-26 2007-04-26 Biomet Manufacturing Corp. Composition for wound healing using lyophilized skin or skin-derived collagen
US7785634B2 (en) * 2006-02-27 2010-08-31 Globus Medical, Inc. Bone graft materials derived from mineralized gelatin
US7892577B2 (en) * 2006-02-27 2011-02-22 Globus Medical, Inc. Bone graft materials derived from mineralized gelatin
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US20080233203A1 (en) 2007-03-21 2008-09-25 Jennifer Woodell-May Porous orthapedic materials coated with demineralized bone matrix
US20090131886A1 (en) 2007-11-16 2009-05-21 Liu Y King Steerable vertebroplasty system
US20090131867A1 (en) 2007-11-16 2009-05-21 Liu Y King Steerable vertebroplasty system with cavity creation element
US9510885B2 (en) 2007-11-16 2016-12-06 Osseon Llc Steerable and curvable cavity creation system
US9700584B2 (en) 2007-12-21 2017-07-11 Rti Surgical, Inc. Osteoinductive putties and methods of making and using such putties
US20100298832A1 (en) 2009-05-20 2010-11-25 Osseon Therapeutics, Inc. Steerable curvable vertebroplasty drill
BR112012027708B1 (pt) 2010-04-29 2021-03-09 Dfine, Inc dispositivo médico para ablação de tecido dentro de um osso de um paciente
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
AU2014262833B2 (en) 2013-05-06 2019-10-31 Bio-Rad Laboratories, Inc. Stabilization of labile analytes in reference materials
FR3020273B1 (fr) 2014-04-25 2021-04-16 Biobank Procede de fabrication de pate osseuse
CA2986702C (fr) 2015-05-21 2023-04-04 David Wang Fibres osseuses corticales demineralisees modifiees
US10549011B2 (en) * 2015-10-26 2020-02-04 Osteolife Biomedical, Llc Bone putty and gel systems and methods
US20170128633A1 (en) 2015-11-10 2017-05-11 Theodore Malinin Bioactive Implants and Methods of Making and Using
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
JP2019534130A (ja) 2016-10-27 2019-11-28 ディーファイン，インコーポレイティド セメント送達チャネルを有する関節接合型骨刀
JP7256119B2 (ja) 2016-11-28 2023-04-11 ディファイン インコーポレイテッド 腫瘍切除装置及び関連する方法
WO2018107036A1 (fr) 2016-12-09 2018-06-14 Dfine, Inc. Dispositifs médicaux pour traiter des tissus durs et procédés associés
EP3565486B1 (fr) 2017-01-06 2021-11-10 Dfine, Inc. Ostéotome avec partie distale pour avancement et articulation simultanés
EP3876856A4 (fr) 2018-11-08 2022-10-12 Dfine, Inc. Dispositif d'ablation de tumeurs et systèmes et procédés apparentés
US11207445B2 (en) 2019-07-09 2021-12-28 Community Blood Center Allograft bone putty and methods of making the same
EP4031040B1 (fr) 2019-09-18 2025-04-09 Merit Medical Systems, Inc. Ostéotome à partie gonflable et articulation multifilaire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172128A (en) * 1975-03-26 1979-10-23 Erhard Thiele Process of degrading and regenerating bone and tooth material and products
US5459241A (en) * 1987-12-30 1995-10-17 Systems Bio Industries Continuous process for the preparation of gelatin from powdered bone, and gelatin obtained
WO1998035653A1 (fr) * 1997-02-13 1998-08-20 Benedict, James, A. Materiau implantable de type mastic, a base de collagene
US6030635A (en) * 1998-02-27 2000-02-29 Musculoskeletal Transplant Foundation Malleable paste for filling bone defects

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932973A (en) 1983-09-30 1990-06-12 El Gendler Cartilage and bone induction by artificially perforated organic bone matrix
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5073373A (en) 1989-09-21 1991-12-17 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
ES2076467T3 (es) 1990-10-31 1995-11-01 El Gendler Membranas flexibles producidas con materia de hueso organica para la reparacion y reconstruccion de partes del esqueleto.
US5092887A (en) 1991-08-12 1992-03-03 El Gendler Artificial ligament produced from demineralized bone for the replacement and augmentation of ligaments, tendons and other fibrous connective tissue
US5314476A (en) 1992-02-04 1994-05-24 Osteotech, Inc. Demineralized bone particles and flowable osteogenic composition containing same
US5507813A (en) 1993-12-09 1996-04-16 Osteotech, Inc. Shaped materials derived from elongate bone particles
US5904716A (en) 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US20020098222A1 (en) * 1997-03-13 2002-07-25 John F. Wironen Bone paste
US20020076429A1 (en) * 1998-01-28 2002-06-20 John F. Wironen Bone paste subjected to irradiative and thermal treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172128A (en) * 1975-03-26 1979-10-23 Erhard Thiele Process of degrading and regenerating bone and tooth material and products
US5459241A (en) * 1987-12-30 1995-10-17 Systems Bio Industries Continuous process for the preparation of gelatin from powdered bone, and gelatin obtained
WO1998035653A1 (fr) * 1997-02-13 1998-08-20 Benedict, James, A. Materiau implantable de type mastic, a base de collagene
US6030635A (en) * 1998-02-27 2000-02-29 Musculoskeletal Transplant Foundation Malleable paste for filling bone defects

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PERRY, C.R.: "Bone repair techniques, bone graft and bone graft substitutes", CLINICAL ORTHOPEADICS AND RELATED RESEARCH, no. 360, March 1999 (1999-03-01), pages 71 - 86, XP002908373 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003324A3 (fr) * 2005-06-30 2007-08-16 Transtissue Technologies Gmbh Greffon acellulaire
US9125871B2 (en) 2005-06-30 2015-09-08 Biotissue Ag Cell-free graft
EP1891990A3 (fr) * 2006-04-19 2008-04-23 Biomet Manufacturing Corp. Composition et appareil pour la réparation osseuse
US8734828B2 (en) 2006-10-06 2014-05-27 Biotissue Ag Matrix-gel graft without cells
EP2144672A1 (fr) * 2007-05-04 2010-01-20 Perth Bone & Tissue Bank Procédé et matériau à libération contrôlée pour traiter l'inflammation
EP2144672A4 (fr) * 2007-05-04 2012-08-08 Perth Bone & Tissue Bank Procédé et matériau à libération contrôlée pour traiter l'inflammation
CN102232073A (zh) * 2008-09-16 2011-11-02 普罗克西梅根有限公司 新化合物i
EP2349365A1 (fr) * 2008-11-04 2011-08-03 Perth Bone & Tissue Bank Matériau de support pour des cellules ostéogéniques
EP2349365A4 (fr) * 2008-11-04 2013-01-23 Perth Bone & Tissue Bank Matériau de support pour des cellules ostéogéniques

Also Published As

Publication number Publication date
DE60140142D1 (de) 2009-11-19
US6576249B1 (en) 2003-06-10
RU2003117454A (ru) 2004-11-27
EP1341545A4 (fr) 2004-08-11
EP1341545B1 (fr) 2009-10-07
EP1341545A1 (fr) 2003-09-10
ATE444759T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
US6576249B1 (en) Bone putty and method
EP1477176B1 (fr) Composition osseuse malléable pour remplir de défauts osseux
US6437018B1 (en) Malleable paste with high molecular weight buffered carrier for filling bone defects
US6326018B1 (en) Flexible sheet of demineralized bone
CA2457372C (fr) Compositions pour combler les imperfections osseuses
USRE38522E1 (en) Malleable paste for filling bone defects
US6458375B1 (en) Malleable paste with allograft bone reinforcement for filling bone defects
US6911212B2 (en) Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects
US9138509B2 (en) Composition for filling bone defects
US20060204544A1 (en) Allograft bone composition having a gelatin binder
RU2407552C2 (ru) Инъецируемый композитный материал, пригодный для использования в качестве заменителя костной ткани
US20120205274A1 (en) Allograft bone composition having a gelatin binder
JP2001509419A (ja) 成形可能な生物活性組成物
AU784006B2 (en) Malleable paste for filling bone defects
AU2008200841A1 (en) Composition For Filling Bone Defects

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): RU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001993469

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003117454

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001993469

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载